Cargando…
Sp17 Protein Expression and Major Histocompatibility Class I and II Epitope Presentation in Diffuse Large B Cell Lymphoma Patients
Improved therapies are urgently needed for patients with diffuse large B cell lymphoma (DLBCL). Success using immune checkpoint inhibitors and chimeric antigen receptor T cell technology has fuelled demand for validated cancer epitopes. Immunogenic cancer testis antigens (CTAs), with their widesprea...
Autores principales: | Ait-Tahar, Kamel, Anderson, Amanda P., Barnardo, Martin, Collins, Graham P., Hatton, Chris S. R., Banham, Alison H., Pulford, Karen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5674480/ https://www.ncbi.nlm.nih.gov/pubmed/29204156 http://dx.doi.org/10.1155/2017/6527306 |
Ejemplares similares
-
Identification and Characterization of Peripheral T-Cell Lymphoma-Associated SEREX Antigens
por: Cooper, Christopher D. O., et al.
Publicado: (2011) -
A novel diffuse large B-cell lymphoma-associated cancer testis antigen encoding a PAS domain protein
por: Liggins, A P, et al.
Publicado: (2004) -
Transmembrane Helices Are an Overlooked Source of Major Histocompatibility Complex Class I Epitopes
por: Bianchi, Frans, et al.
Publicado: (2017) -
Increased Expression of Phosphorylated FADD in Anaplastic Large Cell and Other T-Cell Lymphomas
por: Patel, Suketu, et al.
Publicado: (2014) -
Engineering chimeric human and mouse major histocompatibility complex (MHC) class I tetramers for the production of T-cell receptor (TCR) mimic antibodies
por: Li, Demin, et al.
Publicado: (2017)